Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours

European Journal of Cancer

Volumn 39, Issue 2, 2003, Pages 230-239

  Christov, K T ^a   Shilkaitis, A L ^a   Kim, E S ^a   Steele, V E ^b   Lubet, R A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemoprevention; Mammary tumors; Senescence; Telomerase activity

Indexed keywords

ALITRETINOIN; BROXURIDINE; FENRETINIDE; LIPOFUSCIN; METHYLNITROSOUREA; TAMOXIFEN; TELOMERASE; VOROZOLE;

ANIMAL MODEL; ARTICLE; BREAST TUMOR; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; LIGHT SCATTERING; MYOEPITHELIUM CELL; NONHUMAN; OSMOTIC PUMP; PHENOTYPE; PRIORITY JOURNAL; RAT; RAT STRAIN; SENESCENCE;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL AGING; CYTOPLASMIC GRANULES; FEMALE; FLOW CYTOMETRY; MAMMARY NEOPLASMS, EXPERIMENTAL; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TELOMERASE;

EID: 0037222576     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00497-5     Document Type: Article

References (35)

1. Smith J.R., Pereira-Smith O.M. Replicative senescence. implication for in vivo aging and tumor suppression Science. 273:1998;63-67.
2. Holt S.E., Shay J.W., Wright W.E. Refining the telomere-telomerase hypothesis of aging and cancer. Nature Biotech. 14:1996;836-839.
3. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., Klingelhutz A.J. Both Rb/p16ink4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 396:1998;84-88.
4. Dimri G.P., Xinhua L., Basile G.et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci., USA. 92:1995;9363-9367.
5. Duncan I.L., Reddel R.R. Genetic changes associated with immortalization. Biochemistry. 62:1997;1263-1274.
6. Chang B.D., Watanabe K., Broude E.V.et al. Effects of p21waf1/Cip1/Sdi1 on cellular gene expression. implications for carcinogenesis, senescence, and age-related diseases Proc Nat Acad Sci USA. 97:2000;4291-4296.
7. Xu H.J., Zhou Y., Ji W.et al. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene. 15:1997;2589-2596.
8. Sugrue M.M., Shin D.Y., Lee S.W., Aaronson S.A. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl Acad Sci USA. 94:1997;9648-9653.
9. Campisi J. The biology of replicative senescence. Eur J Cancer. 33:1997;703-709.
10. Miller A.L., Frost R.G., O'Brian J.S. Purification of human liver acid b-D-galactosidase using affinity chromatography. Analyt Biochem. 74:1976;537-545.
11. Chang D.C., Broudy E., Dokmanovic D.et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59:1999;3761-3767.
12. Bednarek A., Shilkaitis A., Green A.et al. Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl) retinamide treated mammary tumors. Carcinogenesis. 20:1999;879-883.
13. Russo J., Russo I.H., van Zwieten M.J., Rogers A.E., Gustersson B. Classification of neoplastic and non-neoplastic lesions of the rat mammary gland. Jones T.C., Mohr U., Hunt R.D. Integument and Mammary Glands, Monographs on Pathology of Laboratory Animals. 1989;275-340 Springer, New York, Berlin, Heidelberg.
14. Jordan V.G., Morrow M. Tamoxifen, reloxifene, and the prevention of breast cancer. Endocrine Reviews. 20:1999;253-278.
15. Lubet R.A., Steele V.E., DeCoster R.et al. Chemopreventive effects of aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis. 19:1998;1345-1351.
16. Moon R.C., Mehta R.G., Rao K.V.N. Retinoids and cancer in experimental animals. The Retinoids: Biology, Chemistry, and Medicine. Sporn MB, Roberts, AB, Goodman DS2nd ed. 1994;Raven Press New York.
17. Gottardis M., Lamph W.W., Shalinski D.R., Wellstein D.R., Heyman R. Efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat. 38:1996;85-96.
18. Christov K., Swanson S., Guzman R., Thordarson G., Talamantes F., Nandi S. Kinetics of mammary epithelial cell proliferation in pituitary isografted Balb/c mice. Carcinogenesis. 16:1993;101-106.
19. Sherwood S.W., Rush D., Elsworth J.L., Schimke R.T., Defining cellular senescence in I.M.R. 90 cells. A flow cytometric analysis Proc Natl Acad Sci USA. 85:1988;9086-9090.
20. Pearse AGE. Histochemistry, Vol.I, 4th Ed. London, 1985.
21. Vindelov L.L., Christiansen I.J. A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry. 11:1990;753-770.
22. Piatyszek M.A., Kim N.W., Weinrich S.L. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci. 17:1995;1-15.
23. Bednareck A., Sahin A., Brenner A.J., Johnston D.A., Aldaz C.M. Analysis of telomerase activity levels in breast cancer. positive detection at the in situ breast carcinoma stage Clinic Cancer Res. 3:1997;11-16.
24. Bednarek A.K., Chu Y., Aldaz C.M. Constitutive telomerase activity in cells with tissue-renewing potential from oestrogen regulated rat tissues. Oncogene. 16:1998;381-385.
25. Christov K., Shilkaitis A., Green A.et al. Cellular responses of mammary tumors to aromatase inhibitors, effects of Vorozole. Breast Cancer Res Treat. 60:2000;117-128.
26. Green A., Shilkaitis A., Christov K. 4-HPR selectively suppresses the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary carcinogenesis. Carcinogenesis. 20:1999;1535-1540.
27. Snedecor G.J.W., Cochran W.G. Statistical Methods, vol. 11. 8th edn. 1998;Iowa State Univ Press, IA, Ames.
28. Russo J., Russo I.H. Influence of differentiation and cell kinetics on the susceptibility of rat mammary gland to carcinogenesis. Cancer Res. 40:1980;2677-2687.
29. Varon D., Jiang C., Hedican C.et al. Telomerase activity in the normal and neoplastic rat mammary gland. Cancer Res. 57:1997;5605-5609.
30. Herbert B.S., Wright A.C., Passons C.M.et al. Effects of chemopreventive and antitelomerase agents on the spontaneous imortalization of breast epithelial cells. J Nat Cancer Inst. 93:2001;39-45.
31. Wang X., Wong S.C., Pan J.et al. Evidence of cisplatin-induced senescence-like growth arrest in nasopharingeal carcinoma cells. Cancer Res. 58:1998;5019-5022.
32. Hoos A., Hepp H.H., Kaul S., Ahlert T., Bastert G., Wallwiener D. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer. 79:1998;8-12.
33. LeBourhis X., Toilon R.A., Boilly B., Hondermark H. Autocrine and paracrine growth inhibitors of breast cancer cells. Breast Cancer Res. Treat. 60:2000;251-258.
34. Kelloff G.J., Hawk E.T., Crowell J.A.et al. Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev Suppl. 2:1996;79-85.
35. Rables S.J., Adami J.R. Agents that cause DNA double strand breaks lead to p16INC4A enrichment and premature senescence of normal fibroblasts. Oncogene. 16:1998;1113-1123.